<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01611090</url>
  </required_header>
  <id_info>
    <org_study_id>CR100840</org_study_id>
    <secondary_id>PCI-32765CLL3001</secondary_id>
    <secondary_id>2012-000600-15</secondary_id>
    <secondary_id>U1111-1135-3745</secondary_id>
    <nct_id>NCT01611090</nct_id>
  </id_info>
  <brief_title>A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmacyclics LLC.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the safety and efficacy of Ibrutinib administered in
      combination with bendamustine and rituximab in patients with relapsed or refractory chronic
      lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized (patients will be assigned by chance to study treatments), double-blind
      (patients and study personnel will not know the identity of study treatments), placebo (an
      inactive substance that is compared with a drug to test whether the drug has a real effect in
      a clinical trial)-controlled study to determine the benefits and risks of combining ibrutinib
      with bendamustine and rituximab (BR) in patients with relapsed or refractory CLL/SLL
      following at least 1 line of prior systemic therapy. Approximately 580 patients will be
      randomized in a 1:1 ratio to either treatment arm A (placebo) or treatment arm B (ibrutinib
      420 mg).

      Study medication will be administered orally once daily on a continuous schedule. All
      patients will receive BR as the background therapy plus either ibrutinib or placebo for a
      maximum of 6 cycles, after which treatment with ibrutinib or placebo will continue until
      disease progression or unacceptable toxicity.

      A treatment cycle will be defined as 28 days. The study will include a screening phase, a
      treatment phase, and a follow-up phase. Study end is defined as when either 80% of the
      patients have died or 5 years after the last patient is randomized into the study, whichever
      occurs first.

      Patients in treatment arm A (placebo) who complete the treatment phase, with disease
      progression or (after interim analysis) meet International Workshop on Chronic Lymphocytic
      Leukemia (IWCLL) criteria for treatment, may crossover to ibrutinib treatment (as in
      treatment arm B), at the investigators discretion. This open-label, next-line treatment with
      ibrutinib will continue until disease progression, unacceptable toxicity, withdrawal from
      study, or until the study end, whichever occurs earlier. One interim analysis is planned for
      the study. Efficacy evaluations will include computed tomography scans, laboratory testing,
      focused physical examinations, bone marrow biopsy and aspirate, and assessment of
      patient-reported outcomes. In both treatment arms, samples for the development of a
      population-based pharmacokinetic (PK; study of what the body does to a drug) approach will be
      collected. Safety will be assessed throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 19, 2012</start_date>
  <completion_date type="Actual">January 23, 2019</completion_date>
  <primary_completion_date type="Actual">January 23, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>PFS was defined as the interval between the date of randomization and the date of disease progression or death, whichever was first reported. IWCLL 2008 criteria for PD: New enlarged nodes &gt;1.5 cm, new hepatomegaly or splenomegaly, or other new organ infiltrates, bone lesion, ascites, or pleural effusion confirmed due to chronic lymphocytic leukemia (CLL); &gt;=50% increase in existing lymph nodes; &gt;=50% increase in enlargement of liver or spleen; &gt;=50% increase from baseline in lymphocyte count (and to &gt;=5*10^9/L) or &gt;=50% increase from nadir count confirmed on &gt;=2 serial assessments if absolute lymphocyte count (ALC) &gt;=30,000 per microliter and lymphocyte doubling time is rapid, unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b [Hgb] or platelets) attributable to CLL; and transformation to a more aggressive histology.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>ORR defined as number of participants achieving a complete response (CR), complete response with incomplete marrow recovery (CRi), nodular partial response (nPR) or partial response (PR). IWCLL 2008 criteria: CR- No lymphadenopathy and hepatosplenomegaly, no constitutional symptoms, neutrophils &gt;1.5*10^9/liter (L), platelets &gt;100*10^9/L, Hgb &gt;11 gram per deciliter (g/dL) and absolute lymphocyte count &lt;4000/microliter (mcL); CRi- CR with incomplete recovery of bone marrow; nPR- participants meet criteria for CR, but the bone marrow biopsy shows B-lymphoid nodules, may represent a clonal infiltrate; PR-2 of the following when abnormal at baseline: &gt;=50% decrease in ALC, &gt;=50% decrease in sum products of up to 6 lymph nodes, &gt;=50% decrease in enlargement of spleen or liver; and 1 of the following: neutrophils &gt;1.5*10^9/L, Platelets &gt;100*10^9/L and Hgb&gt;11 g/dL or &gt;=50% improvement over baseline in any of these; no new enlarged nodes or new hepatosplenomegaly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>OS was defined as the interval between the date of randomization and the date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Minimal Residual Disease (MRD)-Negative Response</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>MRD-negative response was defined as the percentage of participants who reach MRD negative disease status (less than 1 chronic lymphocytic leukemia [CLL] cell per 10,000 leukocytes) in either bone marrow or peripheral blood. All randomized participants were included in this analysis. Participants with missing MRD data were considered non-responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Sustained Hematologic Improvement</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Sustained hematologic improvement was defined as hematological improvement that was sustained continuously for greater than or equal to (&gt;=) 56 days without blood transfusion or growth factors: 1) Platelet counts greater than (&gt;)100* 109/liter (L) if baseline less than or equal to (&lt;=) 100*109/L or increase &gt;= 50 percent (%) over baseline; 2) Hemoglobin &gt;11 gram per deciliters (g/dL) if baseline &lt;= 11 g/dL or increase &gt;= 2 g/dL over baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Clinically Meaningful Improvement in FACIT-Fatigue Scale</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Time to improvement is defined as the time interval (months) from randomization to the first observation of improvement. FACIT-Fatigue is an instrument for use as a measure of the effect of fatigue in patients with cancer and other chronic diseases. Responses to the 13-item FACIT Fatigue Scale are reported on a 5‚Äêpoint categorical response scale ranging from 0 (not at all) to 4 (very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Relevant Shifts in Disease-Related Symptoms</measure>
    <time_frame>From the date of randomization to disease progression (Up to 2 years)</time_frame>
    <description>The disease-related symptoms included fatigue, weight loss, fevers, night sweats, abdominal discomfort/splenomegaly and anorexia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Received Subsequent Antineoplastic Therapy</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Number of participants who received subsequent antineoplastic therapy was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Beta2 Microglobulin at End of Treatment (EOT)</measure>
    <time_frame>Baseline to EOT (Up to 2 years)</time_frame>
    <description>Change from baseline in beta2 microglobulin at end of treatment at time of primary analysis was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FACIT-Fatigue Scale at End of Treatment</measure>
    <time_frame>Baseline to EOT (up to 2 years)</time_frame>
    <description>FACIT-Fatigue is an instrument for use as a measure of the effect of fatigue in patients with cancer and other chronic diseases. Responses to the 13-item FACIT Fatigue Scale are reported on a 5‚Äêpoint categorical response scale ranging from 0 (not at all) to 4 (very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EORTC QLQ-C30 Physical Functioning Score at End of Treatment</measure>
    <time_frame>Baseline to EOT (up to 2 years)</time_frame>
    <description>EORTC QLQ-C30 Physical Functioning Score is a questionnaire to assess quality of life of cancer patients. It is composed of 30 items, multi-item measure (28 items) and 2 single-item measures. For the multiple item measure, 4-point scale is used and the score for each item range from &quot;1 = not at all&quot; to &quot;4 = very much&quot;. Higher scores indicate worsening. The 2 single-item measure involves question about the overall health and overall quality of life which was rated on a 7-point scale ranging from &quot;1 = very poor&quot; to &quot;7 = excellent&quot;. Lower scores indicate worsening. All scale and item scores were linearly transformed to be in range from 0-100. A higher score represents a higher (better) level of functioning, or a higher (worse) level of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EORTC QLQ-CLL 16 Domain Scores at End of Treatment</measure>
    <time_frame>Baseline to EOT (up to 2 years)</time_frame>
    <description>The EORTC QLQ-CLL 16 is a 16-item disease specific module that comprises 5 domains of patient-reported health status important in CLL. There are three multi-item scales that include fatigue (2 items), treatment side effects and disease symptoms (8 items), and infection (4 items), and 2 single-item scales on social activities and future health worries. Responses are measured on a 4 point scale ranging from 1 (not at all) to 4 (very much).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Visual Analog Scale at End of Treatment</measure>
    <time_frame>Baseline to EOT (up to 2 years)</time_frame>
    <description>The EQ-5D questionnaire is a brief, generic health-related quality of life assessment (HRQOL) that can also be used to incorporate participant preferences into health economic evaluations. The EQ-5D questionnaire assesses HRQOL in terms of degree of limitation on 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and as overall health using a visual analog scale with response options ranging from 0 (worst imaginable health) to 100 (best imaginable health).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Utility Score Scale at End of Treatment</measure>
    <time_frame>Baseline to EOT (up to 2 years)</time_frame>
    <description>The EuroQol-5 is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1. High score indicating a high level of utility.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">578</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Ibrutinib + BR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib 420 mg will be administered orally once daily on a continuous schedule. All subjects will receive background therapy with bendamustine and rituximab (BR) for a maximum of 6 cycles (a cycle is defined as 28 days, with the exception of Cycle 1, which will be 29 days to allow for rituximab dosing prior to bendamustine and study medication).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + BR</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo will be administered orally once daily on a continuous schedule. All subjects will receive background therapy with BR for a maximum of 6 cycles (a cycle is defined as 28 days, with the exception of Cycle 1, which will be 29 days to allow for rituximab dosing prior to bendamustine and study medication).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>Type=exact number, unit=mg, number=420 , form=capsule, route=oral use. Capsule is taken once daily continuously.</description>
    <arm_group_label>Ibrutinib + BR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine hydrochloride</intervention_name>
    <description>Type=exact number, unit=mg, number=70 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Days 2-3 and Cycles 2-6, Days 1-2.</description>
    <arm_group_label>Ibrutinib + BR</arm_group_label>
    <arm_group_label>Placebo + BR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Type=exact number, unit=mg, number=375 mg/m2 and 500 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Day 1, and Cycles 2-6, Day 1, respectively.</description>
    <arm_group_label>Ibrutinib + BR</arm_group_label>
    <arm_group_label>Placebo + BR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Form=capsule, route=oral use. Capsule is taken once daily continuously.</description>
    <arm_group_label>Placebo + BR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
             that meets protocol-defined criteria

          -  Active disease meeting at least 1 of the International Workshop on Chronic Lymphocytic
             Leukemia 2008 criteria for requiring treatment

          -  Measurable nodal disease by computed tomography

          -  Relapsed or refractory CLL or SLL following at least 1 prior line of systemic therapy
             consisting of at least 2 cycles of a chemotherapy-containing regimen

          -  Eastern Cooperative Oncology Group Performance Status score of 0 or 1

          -  Hematology and biochemical values within protocol-defined limits

          -  Agrees to protocol-defined use of effective contraception

          -  Women of childbearing potential must have negative blood or urine pregnancy test at
             screening

        Exclusion Criteria:

          -  Recent therapeutic interventions within 3 (chemotherapy/radiotherapy) to 10 weeks
             (immunotherapy)

          -  Prior treatment with ibrutinib or other Bruton's tyrosine kinase inhibitors or prior
             randomization in any other clinical study evaluating ibrutinib

          -  The presence of deletion of the short arm of chromosome 17

          -  Patients previously treated with a bendamustine-containing regimen who did not achieve
             a response or who relapsed and required treatment within 24 months of treatment with
             that regimen

          -  Patients for whom the goal of therapy is tumor debulking prior to stem cell transplant

          -  Received a hematopoietic stem cell transplant

          -  Known central nervous system leukemia/lymphoma or Richter's transformation

          -  Patients with uncontrolled autoimmune hemolytic anemia or autoimmune thrombocytopenia

          -  Chronic use of corticosteroids

          -  History of prior malignancy, except: malignancy treated with curative intent and with
             no known active disease present for &gt;=3 years before randomization; adequately treated
             non-melanoma skin cancer or lentigo maligna without evidence of disease; adequately
             treated cervical carcinoma in situ without evidence of disease

          -  History of stroke or intracranial hemorrhage within 6 months prior to randomization;
             or clinically significant cardiovascular disease

          -  Requires anticoagulation with warfarin or equivalent vitamin K antagonists or
             treatment with strong CYP3A4/5 inhibitors

          -  Known history of human immunodeficiency virus or hepatitis C, or active infection with
             hepatitis B or C

          -  Any uncontrolled active systemic infection or any life-threatening illness, medical
             condition, or organ system dysfunction which, in the investigator's opinion, could
             compromise the patient's safety, interfere with the absorption or metabolism of
             ibrutinib capsules, or put the study outcomes at undue risk

          -  A woman who is pregnant or breast feeding, or a man who plans to father a child while
             enrolled in this study or within 3 months after the last dose of study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goshen</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Battle Creek</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dunkirk</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hawthorne</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salvador</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver N/a</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Floridablanca</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 10</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 2</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris Cedex 13</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pierre Benite</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aschaffenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frechen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Homburg/Saar</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kassel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koblenz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>K√∂ln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>K√øln N/a</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lebach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mutlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>W√ºrzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thessalonikis</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nahariya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Netanya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petah Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ramat-Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oaxaca</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brzozow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chorz√≥w</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Opole</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Slupsk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ponta Delgada</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dzerzhinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krasnodar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow N/a</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nizhniy Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Obninsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perm</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rostov-Na-Donu</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ryazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sochi</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St.-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Syktyvkar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>L'hospitalet De Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>G√∂teborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huddinge</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>UME√•</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kayseri</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cherkassy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dnepropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Khakhiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Khmelnitskiy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vinnitsa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Harrow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sheffield Yorks</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Puerto Rico</country>
  </removed_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 15, 2012</study_first_submitted>
  <study_first_submitted_qc>May 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2012</study_first_posted>
  <results_first_submitted>January 23, 2020</results_first_submitted>
  <results_first_submitted_qc>February 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 3, 2020</results_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic lymphocytic leukemia</keyword>
  <keyword>Small lymphocytic lymphoma</keyword>
  <keyword>Relapsed or refractory chronic lymphocytic leukemia</keyword>
  <keyword>Relapsed or refractory small lymphocytic lymphoma</keyword>
  <keyword>Ibrutinib</keyword>
  <keyword>PCI-32765</keyword>
  <keyword>JNJ-54179060</keyword>
  <keyword>Bruton's tyrosine kinase inhibitor</keyword>
  <keyword>Bendamustine</keyword>
  <keyword>Rituximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 21, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT01611090/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 9, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT01611090/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 578 participants were enrolled in the study. Among these, 289 participants were randomized in each ibrutinib + bendamustine/rituximab (BR) treatment group and placebo+BR treatment group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ibrutinib+BR</title>
          <description>Participants received ibrutinib 420 milligram (mg) (3 * 140 mg capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles ibrutinib alone was administered until disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="P2">
          <title>Placebo+BR</title>
          <description>Participants received placebo (3 capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles placebo alone was administered until disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="P3">
          <title>Crossover to Ibrutinib</title>
          <description>Participants in the placebo+BR treatment group could cross over to receive next-line ibrutinib treatment (420 mg [3 * 140 mg capsules] orally once daily on a 28-day cycle) at the discretion of the investigator at the time of disease progression or if International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria for treatment were met.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomized Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="289"/>
                <participants group_id="P2" count="289"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="287"/>
                <participants group_id="P2" count="287"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="259"/>
                <participants group_id="P2" count="260"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Cross Over (Placebo to Ibrutinib)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="183"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="183"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="178"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ibrutinib+BR</title>
          <description>Participants received ibrutinib 420 milligram (mg) (3 * 140 mg capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles ibrutinib alone was administered until disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="B2">
          <title>Placebo+BR</title>
          <description>Participants received placebo (3 capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles placebo alone was administered until disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="289"/>
            <count group_id="B2" value="289"/>
            <count group_id="B3" value="578"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.7" spread="9.82"/>
                    <measurement group_id="B2" value="63.3" spread="9.3"/>
                    <measurement group_id="B3" value="63.5" spread="9.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="196"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="193"/>
                    <measurement group_id="B2" value="189"/>
                    <measurement group_id="B3" value="382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="256"/>
                    <measurement group_id="B2" value="253"/>
                    <measurement group_id="B3" value="509"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="264"/>
                    <measurement group_id="B2" value="264"/>
                    <measurement group_id="B3" value="528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>ARGENTINA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BELGIUM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRAZIL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CANADA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COLOMBIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CZECH REPUBLIC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRANCE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GERMANY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GREECE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ISRAEL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MEXICO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POLAND</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PORTUGAL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RUSSIAN FEDERATION</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SOUTH KOREA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPAIN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SWEDEN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TURKEY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UKRAINE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UNITED KINGDOM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UNITED STATES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>PFS was defined as the interval between the date of randomization and the date of disease progression or death, whichever was first reported. IWCLL 2008 criteria for PD: New enlarged nodes &gt;1.5 cm, new hepatomegaly or splenomegaly, or other new organ infiltrates, bone lesion, ascites, or pleural effusion confirmed due to chronic lymphocytic leukemia (CLL); &gt;=50% increase in existing lymph nodes; &gt;=50% increase in enlargement of liver or spleen; &gt;=50% increase from baseline in lymphocyte count (and to &gt;=5*10^9/L) or &gt;=50% increase from nadir count confirmed on &gt;=2 serial assessments if absolute lymphocyte count (ALC) &gt;=30,000 per microliter and lymphocyte doubling time is rapid, unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b [Hgb] or platelets) attributable to CLL; and transformation to a more aggressive histology.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Intent to treat (ITT) population included all participants randomized into the study regardless of treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibrutinib+BR</title>
            <description>Participants received ibrutinib 420 milligram (mg) (3 * 140 mg capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles ibrutinib alone was administered until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+BR</title>
            <description>Participants received placebo (3 capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles placebo alone was administered until disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>PFS was defined as the interval between the date of randomization and the date of disease progression or death, whichever was first reported. IWCLL 2008 criteria for PD: New enlarged nodes &gt;1.5 cm, new hepatomegaly or splenomegaly, or other new organ infiltrates, bone lesion, ascites, or pleural effusion confirmed due to chronic lymphocytic leukemia (CLL); &gt;=50% increase in existing lymph nodes; &gt;=50% increase in enlargement of liver or spleen; &gt;=50% increase from baseline in lymphocyte count (and to &gt;=5*10^9/L) or &gt;=50% increase from nadir count confirmed on &gt;=2 serial assessments if absolute lymphocyte count (ALC) &gt;=30,000 per microliter and lymphocyte doubling time is rapid, unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b [Hgb] or platelets) attributable to CLL; and transformation to a more aggressive histology.</description>
          <population>Intent to treat (ITT) population included all participants randomized into the study regardless of treatment actually received.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="289"/>
                <count group_id="O2" value="289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.12" lower_limit="55.43" upper_limit="NA">Here, NA indicates upper limit of confidence interval (CI) was not estimable due to insufficient number of events.</measurement>
                    <measurement group_id="O2" value="14.32" lower_limit="13.86" upper_limit="16.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.229</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.183</ci_lower_limit>
            <ci_upper_limit>0.286</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate (ORR)</title>
        <description>ORR defined as number of participants achieving a complete response (CR), complete response with incomplete marrow recovery (CRi), nodular partial response (nPR) or partial response (PR). IWCLL 2008 criteria: CR- No lymphadenopathy and hepatosplenomegaly, no constitutional symptoms, neutrophils &gt;1.5*10^9/liter (L), platelets &gt;100*10^9/L, Hgb &gt;11 gram per deciliter (g/dL) and absolute lymphocyte count &lt;4000/microliter (mcL); CRi- CR with incomplete recovery of bone marrow; nPR- participants meet criteria for CR, but the bone marrow biopsy shows B-lymphoid nodules, may represent a clonal infiltrate; PR-2 of the following when abnormal at baseline: &gt;=50% decrease in ALC, &gt;=50% decrease in sum products of up to 6 lymph nodes, &gt;=50% decrease in enlargement of spleen or liver; and 1 of the following: neutrophils &gt;1.5*10^9/L, Platelets &gt;100*10^9/L and Hgb&gt;11 g/dL or &gt;=50% improvement over baseline in any of these; no new enlarged nodes or new hepatosplenomegaly.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Intent to treat (ITT) population included all participants randomized into the study regardless of treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibrutinib+BR</title>
            <description>Participants received ibrutinib 420 milligram (mg) (3 * 140 mg capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles ibrutinib alone was administered until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+BR</title>
            <description>Participants received placebo (3 capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles placebo alone was administered until disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR)</title>
          <description>ORR defined as number of participants achieving a complete response (CR), complete response with incomplete marrow recovery (CRi), nodular partial response (nPR) or partial response (PR). IWCLL 2008 criteria: CR- No lymphadenopathy and hepatosplenomegaly, no constitutional symptoms, neutrophils &gt;1.5*10^9/liter (L), platelets &gt;100*10^9/L, Hgb &gt;11 gram per deciliter (g/dL) and absolute lymphocyte count &lt;4000/microliter (mcL); CRi- CR with incomplete recovery of bone marrow; nPR- participants meet criteria for CR, but the bone marrow biopsy shows B-lymphoid nodules, may represent a clonal infiltrate; PR-2 of the following when abnormal at baseline: &gt;=50% decrease in ALC, &gt;=50% decrease in sum products of up to 6 lymph nodes, &gt;=50% decrease in enlargement of spleen or liver; and 1 of the following: neutrophils &gt;1.5*10^9/L, Platelets &gt;100*10^9/L and Hgb&gt;11 g/dL or &gt;=50% improvement over baseline in any of these; no new enlarged nodes or new hepatosplenomegaly.</description>
          <population>Intent to treat (ITT) population included all participants randomized into the study regardless of treatment actually received.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="289"/>
                <count group_id="O2" value="289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.2"/>
                    <measurement group_id="O2" value="66.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>OS was defined as the interval between the date of randomization and the date of death from any cause.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Intent to treat (ITT) population included all participants randomized into the study regardless of treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibrutinib+BR</title>
            <description>Participants received ibrutinib 420 milligram (mg) (3 * 140 mg capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles ibrutinib alone was administered until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+BR</title>
            <description>Participants received placebo (3 capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles placebo alone was administered until disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS was defined as the interval between the date of randomization and the date of death from any cause.</description>
          <population>Intent to treat (ITT) population included all participants randomized into the study regardless of treatment actually received.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="289"/>
                <count group_id="O2" value="289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="70.93" upper_limit="NA">Here, NA indicates median and upper limit of CI was not estimable due to insufficient number of events.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Here, NA indicates median and CI was not estimable due to insufficient number of events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Minimal Residual Disease (MRD)-Negative Response</title>
        <description>MRD-negative response was defined as the percentage of participants who reach MRD negative disease status (less than 1 chronic lymphocytic leukemia [CLL] cell per 10,000 leukocytes) in either bone marrow or peripheral blood. All randomized participants were included in this analysis. Participants with missing MRD data were considered non-responders.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Intent to treat (ITT) population included all participants randomized into the study regardless of treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibrutinib+BR</title>
            <description>Participants received ibrutinib 420 milligram (mg) (3 * 140 mg capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles ibrutinib alone was administered until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+BR</title>
            <description>Participants received placebo (3 capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles placebo alone was administered until disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Minimal Residual Disease (MRD)-Negative Response</title>
          <description>MRD-negative response was defined as the percentage of participants who reach MRD negative disease status (less than 1 chronic lymphocytic leukemia [CLL] cell per 10,000 leukocytes) in either bone marrow or peripheral blood. All randomized participants were included in this analysis. Participants with missing MRD data were considered non-responders.</description>
          <population>Intent to treat (ITT) population included all participants randomized into the study regardless of treatment actually received.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="289"/>
                <count group_id="O2" value="289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7"/>
                    <measurement group_id="O2" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Sustained Hematologic Improvement</title>
        <description>Sustained hematologic improvement was defined as hematological improvement that was sustained continuously for greater than or equal to (&gt;=) 56 days without blood transfusion or growth factors: 1) Platelet counts greater than (&gt;)100* 109/liter (L) if baseline less than or equal to (&lt;=) 100*109/L or increase &gt;= 50 percent (%) over baseline; 2) Hemoglobin &gt;11 gram per deciliters (g/dL) if baseline &lt;= 11 g/dL or increase &gt;= 2 g/dL over baseline.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>ITT population included all participants randomized into the study regardless of treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibrutinib+BR</title>
            <description>Participants received ibrutinib 420 milligram (mg) (3 * 140 mg capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles ibrutinib alone was administered until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+BR</title>
            <description>Participants received placebo (3 capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles placebo alone was administered until disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sustained Hematologic Improvement</title>
          <description>Sustained hematologic improvement was defined as hematological improvement that was sustained continuously for greater than or equal to (&gt;=) 56 days without blood transfusion or growth factors: 1) Platelet counts greater than (&gt;)100* 109/liter (L) if baseline less than or equal to (&lt;=) 100*109/L or increase &gt;= 50 percent (%) over baseline; 2) Hemoglobin &gt;11 gram per deciliters (g/dL) if baseline &lt;= 11 g/dL or increase &gt;= 2 g/dL over baseline.</description>
          <population>ITT population included all participants randomized into the study regardless of treatment actually received.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="289"/>
                <count group_id="O2" value="289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7"/>
                    <measurement group_id="O2" value="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8"/>
                    <measurement group_id="O2" value="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Clinically Meaningful Improvement in FACIT-Fatigue Scale</title>
        <description>Time to improvement is defined as the time interval (months) from randomization to the first observation of improvement. FACIT-Fatigue is an instrument for use as a measure of the effect of fatigue in patients with cancer and other chronic diseases. Responses to the 13-item FACIT Fatigue Scale are reported on a 5‚Äêpoint categorical response scale ranging from 0 (not at all) to 4 (very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score).</description>
        <time_frame>Up to 2 years</time_frame>
        <population>ITT population included all participants randomized into the study regardless of treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibrutinib+BR</title>
            <description>Participants received ibrutinib 420 milligram (mg) (3 * 140 mg capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles ibrutinib alone was administered until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+BR</title>
            <description>Participants received placebo (3 capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles placebo alone was administered until disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Clinically Meaningful Improvement in FACIT-Fatigue Scale</title>
          <description>Time to improvement is defined as the time interval (months) from randomization to the first observation of improvement. FACIT-Fatigue is an instrument for use as a measure of the effect of fatigue in patients with cancer and other chronic diseases. Responses to the 13-item FACIT Fatigue Scale are reported on a 5‚Äêpoint categorical response scale ranging from 0 (not at all) to 4 (very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score).</description>
          <population>ITT population included all participants randomized into the study regardless of treatment actually received.</population>
          <units>Months</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="289"/>
                <count group_id="O2" value="289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="4.7" upper_limit="10.7"/>
                    <measurement group_id="O2" value="4.6" lower_limit="2.8" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Relevant Shifts in Disease-Related Symptoms</title>
        <description>The disease-related symptoms included fatigue, weight loss, fevers, night sweats, abdominal discomfort/splenomegaly and anorexia.</description>
        <time_frame>From the date of randomization to disease progression (Up to 2 years)</time_frame>
        <population>ITT population included all participants randomized into the study regardless of treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibrutinib+BR</title>
            <description>Participants received ibrutinib 420 milligram (mg) (3 * 140 mg capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles ibrutinib alone was administered until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+BR</title>
            <description>Participants received placebo (3 capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles placebo alone was administered until disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Relevant Shifts in Disease-Related Symptoms</title>
          <description>The disease-related symptoms included fatigue, weight loss, fevers, night sweats, abdominal discomfort/splenomegaly and anorexia.</description>
          <population>ITT population included all participants randomized into the study regardless of treatment actually received.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="289"/>
                <count group_id="O2" value="289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Received Subsequent Antineoplastic Therapy</title>
        <description>Number of participants who received subsequent antineoplastic therapy was reported.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Safety analysis set included all the randomized participants who received at least 1 dose of study drug or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibrutinib+BR</title>
            <description>Participants received ibrutinib 420 milligram (mg) (3 * 140 mg capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles ibrutinib alone was administered until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+BR</title>
            <description>Participants received placebo (3 capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles placebo alone was administered until disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Received Subsequent Antineoplastic Therapy</title>
          <description>Number of participants who received subsequent antineoplastic therapy was reported.</description>
          <population>Safety analysis set included all the randomized participants who received at least 1 dose of study drug or placebo.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Beta2 Microglobulin at End of Treatment (EOT)</title>
        <description>Change from baseline in beta2 microglobulin at end of treatment at time of primary analysis was reported.</description>
        <time_frame>Baseline to EOT (Up to 2 years)</time_frame>
        <population>ITT population included all participants randomized into the study regardless of treatment actually received. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibrutinib+BR</title>
            <description>Participants received ibrutinib 420 milligram (mg) (3 * 140 mg capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles ibrutinib alone was administered until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+BR</title>
            <description>Participants received placebo (3 capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles placebo alone was administered until disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Beta2 Microglobulin at End of Treatment (EOT)</title>
          <description>Change from baseline in beta2 microglobulin at end of treatment at time of primary analysis was reported.</description>
          <population>ITT population included all participants randomized into the study regardless of treatment actually received. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this endpoint.</population>
          <units>milligram per liter (mg/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="1.77"/>
                    <measurement group_id="O2" value="-0.23" spread="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FACIT-Fatigue Scale at End of Treatment</title>
        <description>FACIT-Fatigue is an instrument for use as a measure of the effect of fatigue in patients with cancer and other chronic diseases. Responses to the 13-item FACIT Fatigue Scale are reported on a 5‚Äêpoint categorical response scale ranging from 0 (not at all) to 4 (very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score).</description>
        <time_frame>Baseline to EOT (up to 2 years)</time_frame>
        <population>ITT population included all participants randomized into the study regardless of treatment actually received. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibrutinib+BR</title>
            <description>Participants received ibrutinib 420 milligram (mg) (3 * 140 mg capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles ibrutinib alone was administered until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+BR</title>
            <description>Participants received placebo (3 capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles placebo alone was administered until disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FACIT-Fatigue Scale at End of Treatment</title>
          <description>FACIT-Fatigue is an instrument for use as a measure of the effect of fatigue in patients with cancer and other chronic diseases. Responses to the 13-item FACIT Fatigue Scale are reported on a 5‚Äêpoint categorical response scale ranging from 0 (not at all) to 4 (very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score).</description>
          <population>ITT population included all participants randomized into the study regardless of treatment actually received. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this endpoint.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="11.22"/>
                    <measurement group_id="O2" value="0.0" spread="11.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in EORTC QLQ-C30 Physical Functioning Score at End of Treatment</title>
        <description>EORTC QLQ-C30 Physical Functioning Score is a questionnaire to assess quality of life of cancer patients. It is composed of 30 items, multi-item measure (28 items) and 2 single-item measures. For the multiple item measure, 4-point scale is used and the score for each item range from &quot;1 = not at all&quot; to &quot;4 = very much&quot;. Higher scores indicate worsening. The 2 single-item measure involves question about the overall health and overall quality of life which was rated on a 7-point scale ranging from &quot;1 = very poor&quot; to &quot;7 = excellent&quot;. Lower scores indicate worsening. All scale and item scores were linearly transformed to be in range from 0-100. A higher score represents a higher (better) level of functioning, or a higher (worse) level of symptoms.</description>
        <time_frame>Baseline to EOT (up to 2 years)</time_frame>
        <population>ITT population included all participants randomized into the study regardless of treatment actually received. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibrutinib+BR</title>
            <description>Participants received ibrutinib 420 milligram (mg) (3 * 140 mg capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles ibrutinib alone was administered until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+BR</title>
            <description>Participants received placebo (3 capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles placebo alone was administered until disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EORTC QLQ-C30 Physical Functioning Score at End of Treatment</title>
          <description>EORTC QLQ-C30 Physical Functioning Score is a questionnaire to assess quality of life of cancer patients. It is composed of 30 items, multi-item measure (28 items) and 2 single-item measures. For the multiple item measure, 4-point scale is used and the score for each item range from &quot;1 = not at all&quot; to &quot;4 = very much&quot;. Higher scores indicate worsening. The 2 single-item measure involves question about the overall health and overall quality of life which was rated on a 7-point scale ranging from &quot;1 = very poor&quot; to &quot;7 = excellent&quot;. Lower scores indicate worsening. All scale and item scores were linearly transformed to be in range from 0-100. A higher score represents a higher (better) level of functioning, or a higher (worse) level of symptoms.</description>
          <population>ITT population included all participants randomized into the study regardless of treatment actually received. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this endpoint.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="16.34"/>
                    <measurement group_id="O2" value="-4.1" spread="22.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in EORTC QLQ-CLL 16 Domain Scores at End of Treatment</title>
        <description>The EORTC QLQ-CLL 16 is a 16-item disease specific module that comprises 5 domains of patient-reported health status important in CLL. There are three multi-item scales that include fatigue (2 items), treatment side effects and disease symptoms (8 items), and infection (4 items), and 2 single-item scales on social activities and future health worries. Responses are measured on a 4 point scale ranging from 1 (not at all) to 4 (very much).</description>
        <time_frame>Baseline to EOT (up to 2 years)</time_frame>
        <population>ITT population included all participants randomized into the study regardless of treatment actually received. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this endpoint. Here, 'n' signifies the number of participants analyzed for the specified symptoms.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibrutinib+BR</title>
            <description>Participants received ibrutinib 420 milligram (mg) (3 * 140 mg capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles ibrutinib alone was administered until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+BR</title>
            <description>Participants received placebo (3 capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles placebo alone was administered until disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EORTC QLQ-CLL 16 Domain Scores at End of Treatment</title>
          <description>The EORTC QLQ-CLL 16 is a 16-item disease specific module that comprises 5 domains of patient-reported health status important in CLL. There are three multi-item scales that include fatigue (2 items), treatment side effects and disease symptoms (8 items), and infection (4 items), and 2 single-item scales on social activities and future health worries. Responses are measured on a 4 point scale ranging from 1 (not at all) to 4 (very much).</description>
          <population>ITT population included all participants randomized into the study regardless of treatment actually received. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this endpoint. Here, 'n' signifies the number of participants analyzed for the specified symptoms.</population>
          <units>Units on the scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lost weight</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.86"/>
                    <measurement group_id="O2" value="0.0" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dry mouth</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.96"/>
                    <measurement group_id="O2" value="0.1" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bruises</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.61"/>
                    <measurement group_id="O2" value="0.0" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal discomfort</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.81"/>
                    <measurement group_id="O2" value="0.0" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature going up and down</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.93"/>
                    <measurement group_id="O2" value="0.0" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Night sweats</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="0.92"/>
                    <measurement group_id="O2" value="-0.3" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin problems</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.14"/>
                    <measurement group_id="O2" value="0.3" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feel ill</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="1.08"/>
                    <measurement group_id="O2" value="0.2" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feel lethargic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="1.01"/>
                    <measurement group_id="O2" value="0.0" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Felt slowed down</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.80"/>
                    <measurement group_id="O2" value="0.0" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limited in planning activities</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.97"/>
                    <measurement group_id="O2" value="0.1" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worried about health in the future</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.94"/>
                    <measurement group_id="O2" value="0.0" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trouble with chest infections</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="1.05"/>
                    <measurement group_id="O2" value="0.0" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trouble with other infections</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.07"/>
                    <measurement group_id="O2" value="0.1" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Repeated courses of antibiotics</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.22"/>
                    <measurement group_id="O2" value="0.0" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worried about picking up infection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.96"/>
                    <measurement group_id="O2" value="0.2" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Visual Analog Scale at End of Treatment</title>
        <description>The EQ-5D questionnaire is a brief, generic health-related quality of life assessment (HRQOL) that can also be used to incorporate participant preferences into health economic evaluations. The EQ-5D questionnaire assesses HRQOL in terms of degree of limitation on 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and as overall health using a visual analog scale with response options ranging from 0 (worst imaginable health) to 100 (best imaginable health).</description>
        <time_frame>Baseline to EOT (up to 2 years)</time_frame>
        <population>ITT population included all participants randomized into the study regardless of treatment actually received. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibrutinib+BR</title>
            <description>Participants received ibrutinib 420 milligram (mg) (3 * 140 mg capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles ibrutinib alone was administered until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+BR</title>
            <description>Participants received placebo (3 capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles placebo alone was administered until disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Visual Analog Scale at End of Treatment</title>
          <description>The EQ-5D questionnaire is a brief, generic health-related quality of life assessment (HRQOL) that can also be used to incorporate participant preferences into health economic evaluations. The EQ-5D questionnaire assesses HRQOL in terms of degree of limitation on 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and as overall health using a visual analog scale with response options ranging from 0 (worst imaginable health) to 100 (best imaginable health).</description>
          <population>ITT population included all participants randomized into the study regardless of treatment actually received. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this endpoint.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="19.58"/>
                    <measurement group_id="O2" value="4.0" spread="18.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Utility Score Scale at End of Treatment</title>
        <description>The EuroQol-5 is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1. High score indicating a high level of utility.</description>
        <time_frame>Baseline to EOT (up to 2 years)</time_frame>
        <population>ITT population included all participants randomized into the study regardless of treatment actually received. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Ibrutinib+BR</title>
            <description>Participants received ibrutinib 420 milligram (mg) (3 * 140 mg capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles ibrutinib alone was administered until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+BR</title>
            <description>Participants received placebo (3 capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles placebo alone was administered until disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Utility Score Scale at End of Treatment</title>
          <description>The EuroQol-5 is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1. High score indicating a high level of utility.</description>
          <population>ITT population included all participants randomized into the study regardless of treatment actually received. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this endpoint.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.28"/>
                    <measurement group_id="O2" value="0.0" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time a signed and dated informed consent form is obtained until 30 days following the last dose of study treatment or until the start of a subsequent systemic antineoplastic therapy, if earlier (up to 5 years)</time_frame>
      <desc>Safety analysis set included all the randomized participants who received at least 1 dose of study drug or placebo.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ibrutinib+BR</title>
          <description>Participants received ibrutinib 420 milligram (mg) (3 * 140 mg capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles ibrutinib alone was administered until disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="E2">
          <title>Placebo+BR</title>
          <description>Participants received placebo (3 capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles placebo alone was administered until disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="E3">
          <title>Crossover to Ibrutinib</title>
          <description>Participants in the placebo+BR treatment group could cross over to receive next-line ibrutinib treatment (420 mg [3 * 140 mg capsules] orally once daily on a 28-day cycle) at the discretion of the investigator at the time of disease progression or if International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria for treatment were met.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="198" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="127" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="105" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Aplasia Pure Red Cell</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Aplastic Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Autoimmune Haemolytic Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Bone Marrow Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Cytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Haemolytic Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Immune Thrombocytopenic Purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Arrhythmia Supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Cardio-Respiratory Arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Cardiovascular Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Carditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Coronary Artery Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Sinus Node Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Sinus Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Ventricular Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Ventricular Flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Addison's Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Maculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Retinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Scleral Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Vitreous Adhesions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Vitreous Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Abdominal Incarcerated Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Anal Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Colitis Ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Duodenal Ulcer Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Gastric Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Intra-Abdominal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Large Intestine Perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Lower Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Mouth Ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Oesophageal Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pancreatitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Complication Associated with Device</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Condition Aggravated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Disease Progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>General Physical Health Deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Infusion Site Extravasation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Mucosal Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Multiple Organ Dysfunction Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pneumatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Sudden Cardiac Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Systemic Inflammatory Response Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Cholecystitis Chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Gallbladder Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Hepatic Cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Hepatitis Toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Hepatocellular Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Hepatosplenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic Reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess Jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Actinomycotic Pulmonary Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Acute Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Arthritis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Ascariasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Atypical Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Brain Abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Breast Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Breast Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary Aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Campylobacter Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Cellulitis Staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Central Nervous System Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Chronic Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Clostridium Difficile Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Clostridium Difficile Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Dacryocystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Dermo-Hypodermitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Disseminated Cryptococcosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Epstein-Barr Virus Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Escherichia Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Escherichia Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Fungal Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Haemophilus Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Hepatitis B Reactivation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Infectious Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Lymphadenitis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Muscle Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Neutropenic Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Nocardiosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Oral Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Periorbital Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Peritonsillar Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pharyngeal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pharyngitis Streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pneumocystis Jirovecii Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pneumonia Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pneumonia Haemophilus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pneumonia Pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pneumonia Streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Progressive Multifocal Leukoencephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pseudomembranous Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pulmonary Tuberculoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pulmonary Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Rash Pustular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Respiratory Syncytial Virus Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Skin Candida</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Skin Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Soft Tissue Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Splenic Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Staphylococcal Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Staphylococcal Skin Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Subcutaneous Abscess</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Tooth Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Tuberculosis of Central Nervous System</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Varicella Zoster Virus Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Femoral Neck Fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Incision Site Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Infusion Related Reaction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pelvic Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pneumoconiosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pneumothorax Traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Post Procedural Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Post Procedural Swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Subdural Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Thoracic Vertebral Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Biopsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Body Temperature Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Prostatic Specific Antigen Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Tumour Lysis Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Chondrocalcinosis Pyrophosphate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Femoroacetabular Impingement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Groin Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Lumbar Spinal Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Muscle Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute Lymphocytic Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Adenosquamous Cell Lung Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Anal Squamous Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Bladder Cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Bronchioloalveolar Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Chronic Myelomonocytic Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Intestinal Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Intraductal Papilloma of Breast</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Lung Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Malignant Melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Malignant Melanoma in Situ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Maxillofacial Sinus Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Metastases to Central Nervous System</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Metastatic Renal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Myelodysplastic Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Myeloproliferative Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Neuroendocrine Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Renal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Renal Cancer Stage I</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Renal Oncocytoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Squamous Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Squamous Cell Carcinoma of Skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Superficial Spreading Melanoma Stage Unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Transitional Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid Sinus Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Cerebral Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Cerebral Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Cerebral Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Cognitive Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Depressed Level of Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Facial Paresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Haemorrhage Intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Haemorrhagic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Loss of Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Meningism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Peripheral Sensory Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Post Herpetic Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Transient Global Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Vascular Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Stress Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Alcoholic Psychosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Completed Suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Mental Status Changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Calculus Bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Nephropathy Toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Renal Impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Ureteric Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Urge Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Urinary Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign Prostatic Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Fibrocystic Breast Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Genital Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pelvic Floor Muscle Weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Penile Dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Uterine Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Uterine Prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Dyspnoea Exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Lung Infiltration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pleuritic Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pulmonary Congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pulmonary Mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pulmonary Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Sleep Apnoea Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Febrile Neutrophilic Dermatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Drug Eruption</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Excessive Granulation Tissue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Hypersensitivity Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pemphigoid</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pemphigus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Rash Erythematous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Rash Maculo-Papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Skin Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic Aneurysm Rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Arterial Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Hypertensive Crisis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Jugular Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Peripheral Arterial Occlusive Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Peripheral Artery Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Peripheral Artery Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Peripheral Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="268" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="271" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="157" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="170" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="159" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Dry Eye</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Gastroesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Mucosal Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Oral Herpes</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Infusion Related Reaction</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Productive Cough</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Viral Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Onychoclasis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Rash Maculo-Papular</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Skin Lesion</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="183"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was planned to end when 80% of randomized participants died or 5 years after last participant randomized, whichever was first. Sponsor terminated study on 23-Jan-2019 (5 year after last participant randomized) and study was considered completed</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Medical Director Clinical Research</name_or_title>
      <organization>Janssen Research &amp; Development, LLC</organization>
      <phone>844-434-4210</phone>
      <email>ClinicalTrialDisclosure@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

